PROVe study: Treatment of MF-CTCL Patients #EORTC2019

PROVe study: Treatment of MF-CTCL Patients #EORTC2019

Cancer-News

1 month
17 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Ellen J. Kim, MD of @PennMedicine explains the PROVe Study on efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies. #EORTC19

________

Dr. Ellen J. Kim, UPENN, Professor of Dermatology, Penn Cutaneous Lymphoma Program, PROVe principal investigator, said: “The rarity of MF-CTCL has resulted in there being limited knowledge available for those affected by this disease, as well as many clinicians. We are pleased to have conducted the PROVe study and to further highlight our findings at the EORTC, as we set out to further expand our knowledge concerning the field of MF and current treatment options. The observational study assessed nearly 300 patients and verified that continued treatment of MF-CTCL patients with chlormethine gel is important and associated with improved patients' health-related quality of life.”

Up Next Autoplay
Observations from PROVe Study #EORTC2019
Observations from PROVe Study #EORTC2019
Category: Non-Hodgkin Lymphoma
27 Views
Cancer-News 1 month
PROVe Study: How Long Are Patients On Therapy? #EORTC2019
PROVe Study: How Long Are Patients On Therapy? #EORTC2019
Category: Non-Hodgkin Lymphoma
14 Views
Cancer-News 1 month
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Category: Non-Hodgkin Lymphoma
12 Views
Cancer-News 1 month
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
Category: Non-Hodgkin Lymphoma
231 Views
cancergrace 4 months
CLL and Non-Hodgkin Lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
CLL and Non-Hodgkin Lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
Category: Non-Hodgkin Lymphoma
123 Views
cancergrace 4 months
Chronic Lymphocytic Leukemia,  Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Category: Non-Hodgkin Lymphoma
115 Views
cancergrace 4 months
The Clinical Study Investigating Mosunetuzumab
The Clinical Study Investigating Mosunetuzumab
Category: Non-Hodgkin Lymphoma
110 Views
obr 10 months
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Category: Non-Hodgkin Lymphoma
47 Views
obr 10 months
Non-hodgkin lymphoma advances in 2018
Non-hodgkin lymphoma advances in 2018
Category: Non-Hodgkin Lymphoma
178 Views
VJHemOnc 1 year